MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Ovid therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.54 17.39

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.46

Max

0.56

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-982K

-10M

Pardavimai

54K

130K

Pelno marža

-7,873.077

Darbuotojai

23

EBITDA

-1.8M

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+489.58% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3.3M

28M

Ankstesnė atidarymo kaina

-16.85

Ankstesnė uždarymo kaina

0.54

Naujienos nuotaikos

By Acuity

50%

50%

154 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-18 21:01; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 20:50; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 20:46; UTC

Uždarbis

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

2025-07-18 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 20:36; UTC

Uždarbis

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

2025-07-18 20:16; UTC

Įsigijimai, susijungimai, perėmimai

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

2025-07-18 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 20:02; UTC

Rinkos pokalbiai

Gold Higher to Close Out Week -- Market Talk

2025-07-18 19:14; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

2025-07-18 19:06; UTC

Rinkos pokalbiai

Oil Futures Snap Two-Week Winning Streak -- Market Talk

2025-07-18 18:24; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

2025-07-18 18:19; UTC

Uždarbis

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

2025-07-18 18:11; UTC

Įsigijimai, susijungimai, perėmimai

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

2025-07-18 18:11; UTC

Uždarbis

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

2025-07-18 17:35; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

2025-07-18 16:29; UTC

Rinkos pokalbiai

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

2025-07-18 16:28; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

2025-07-18 16:22; UTC

Uždarbis

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Financial Services Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Auto & Transport Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Energy & Utilities Roundup: Market Talk

2025-07-18 16:20; UTC

Rinkos pokalbiai
Uždarbis

Basic Materials Roundup: Market Talk

2025-07-18 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-18 16:04; UTC

Uždarbis

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

2025-07-18 15:58; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-18 15:58; UTC

Rinkos pokalbiai

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

2025-07-18 15:47; UTC

Rinkos pokalbiai
Uždarbis

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ovid therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

489.58% į viršų

12 mėnesių prognozė

Vidutinis 2.83 USD  489.58%

Aukščiausias 4 USD

Žemiausias 1.5 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ovid therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

5

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.275 / 0.33Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

154 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.